These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21789003)

  • 21. Simultaneous adjuvant radiotherapy and chemotherapy for stage I and II breast cancer.
    Lamb D; Atkinson C; Joseph D; O'Brien P; Ackland S; Bonaventura A; Dady P; Hamilton C; Spry N; Stewart J; Denham J
    Australas Radiol; 1999 May; 43(2):220-6. PubMed ID: 10901906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent sequencing of full-dose CMF chemotherapy and radiation therapy in early breast cancer has no effect on treatment delivery.
    Faul C; Brufsky A; Gerszten K; Flickinger J; Kunschner A; Jacob H; Vogel V
    Eur J Cancer; 2003 Apr; 39(6):763-8. PubMed ID: 12651201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
    Ejlertsen B; Mouridsen HT; Jensen MB
    Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
    Gogas H; Dafni U; Karina M; Papadimitriou C; Batistatou A; Bobos M; Kalofonos HP; Eleftheraki AG; Timotheadou E; Bafaloukos D; Christodoulou C; Markopoulos C; Briasoulis E; Papakostas P; Samantas E; Kosmidis P; Stathopoulos GP; Karanikiotis C; Pectasides D; Dimopoulos MA; Fountzilas G
    Breast Cancer Res Treat; 2012 Apr; 132(2):609-19. PubMed ID: 22187126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
    Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
    N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial.
    Fernando IN; Bowden SJ; Herring K; Brookes CL; Ahmed I; Marshall A; Grieve R; Churn M; Spooner D; Latief TN; Agrawal RK; Brunt AM; Stevens A; Goodman A; Canney P; Bishop J; Ritchie D; Dunn J; Poole CJ; Rea DW;
    Radiother Oncol; 2020 Jan; 142():52-61. PubMed ID: 31785830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
    Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
    J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results.
    Bonadonna G; Zambetti M; Valagussa P
    JAMA; 1995 Feb; 273(7):542-7. PubMed ID: 7837388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant chemotherapy in locally advanced breast cancer.
    Singh G; Singh DP; Gupta D; Muralikrishna BV
    J Surg Oncol; 1996 Jan; 61(1):38-41. PubMed ID: 8544458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma.
    Bellon JR; Shulman LN; Come SE; Li X; Gelman RS; Silver BJ; Harris JR; Recht A
    Cancer; 2004 Apr; 100(7):1358-64. PubMed ID: 15042668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer.
    Livi L; Saieva C; Borghesi S; De Luca Cardillo C; Scotti V; Mangoni M; Greto D; Cataliotti L; Paiar F; Bianchi S; Biti GP
    J Chemother; 2009 Nov; 21(5):558-65. PubMed ID: 19933048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.
    Di Leo A; Crown J; Nogaret JM; Duffy K; Bartholomeus S; Dolci S; Rowan S; O'Higgins N; Paesmans M; Larsimont D; Riva A; Piccart MJ
    Ann Oncol; 2000 Feb; 11(2):169-75. PubMed ID: 10761751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant chemotherapy in early breast cancer.
    Ejlertsen B
    Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
    Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
    J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm.
    Calais G; Berger C; Descamps P; Chapet S; Reynaud-Bougnoux A; Body G; Bougnoux P; Lansac J; Le Floch O
    Cancer; 1994 Aug; 74(4):1283-8. PubMed ID: 8055449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.
    Johansen J; Overgaard J; Overgaard M
    Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using loco-regional recurrence as an indicator of the quality of breast cancer treatment.
    Ernst MF; Voogd AC; Coebergh JW; Poortmans PM; Roukema JA
    Eur J Cancer; 2004 Mar; 40(4):487-93. PubMed ID: 14962713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T1-T2 breast cancer with four or more positive axillary lymph nodes: adjuvant locoregional radiotherapy with high-dose or standard-dose chemotherapy. Results of an observational study.
    Perrucci E; Aristei C; De Angelis V; Anselmo P; Mascioni F; Gori S; Frattegiani A; Latini P
    Tumori; 2004; 90(4):379-86. PubMed ID: 15510979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer.
    Touboul E; Buffat L; Lefranc JP; Blondon J; Deniaud E; Mammar H; Laugier A; Schlienger M
    Int J Radiat Oncol Biol Phys; 1996 Mar; 34(5):1019-28. PubMed ID: 8600084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.